These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Ramirez S; Li YP; Jensen SB; Pedersen J; Gottwein JM; Bukh J Hepatology; 2014 Feb; 59(2):395-407. PubMed ID: 23913364 [TBL] [Abstract][Full Text] [Related]
7. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Imhof I; Simmonds P Hepatology; 2011 Apr; 53(4):1090-9. PubMed ID: 21480315 [TBL] [Abstract][Full Text] [Related]
9. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833 [TBL] [Abstract][Full Text] [Related]
10. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. López-Labrador FX; Moya A; Gonzàlez-Candelas F Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527 [TBL] [Abstract][Full Text] [Related]
11. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Li YP; Ramirez S; Gottwein JM; Scheel TK; Mikkelsen L; Purcell RH; Bukh J Proc Natl Acad Sci U S A; 2012 May; 109(18):E1101-10. PubMed ID: 22467829 [TBL] [Abstract][Full Text] [Related]
12. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. Gottwein JM; Jensen TB; Mathiesen CK; Meuleman P; Serre SB; Lademann JB; Ghanem L; Scheel TK; Leroux-Roels G; Bukh J J Virol; 2011 Sep; 85(17):8913-28. PubMed ID: 21697486 [TBL] [Abstract][Full Text] [Related]
13. Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747 [TBL] [Abstract][Full Text] [Related]
14. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. Imhof I; Simmonds P J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226 [TBL] [Abstract][Full Text] [Related]
15. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins. Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069 [TBL] [Abstract][Full Text] [Related]
16. Adaptive mutation F772S-enhanced p7-NS4A cooperation facilitates the assembly and release of hepatitis C virus and is associated with lipid droplet enlargement. Duan X; Anwar MI; Xu Z; Ma L; Yuan G; Chen Y; Liu X; Xia J; Zhou Y; Li YP Emerg Microbes Infect; 2018 Aug; 7(1):143. PubMed ID: 30087320 [TBL] [Abstract][Full Text] [Related]
17. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations. Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708 [TBL] [Abstract][Full Text] [Related]